Vertex Pharmaceuticals Incorporated VRTX reported first-quarter 2024 adjusted earnings per share of $4.76, which beat the Zacks Consensus Estimate of $4.10. Earnings increased 56% year over year, ...

Vertex stock surged Monday after its competitor, Sionna TherapeuticsSION, missed the mark for its highly anticipated cystic fibrosis treatment. Sionna's drug, SION-719, lowered sweat chloride by 1 ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...

Vertex Pharmaceuticals Incorporated (VRTX) remains a 'Hold' as upside is constrained by valuation and execution risks outside ...

TRIKAFTA is Vertex Pharma’s flagship triple-combination cystic fibrosis therapy, approved in the US for patients as young as 2 years with at least one F508del mutation, and remains the company’s key ...

I believe Vertex Pharmaceuticals Incorporated's bull run has come to an end. There's a divergence between its stock price growth over the past 5 months and the performance of Journavx and the cystic ...

Don't bet against Vertex Pharmaceuticals in cystic fibrosis.

Narrow-moat Vertex's second-quarter results were in line with our expectations. Product revenue of $2.65 billion represented a 6% increase compared with the prior-year period, and Vertex continues to ...

BOSTON--(BUSINESS WIRE)-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year’s ...